Publications by authors named "Rena Shimano"
Association between baseline medications plus neutrophil-to-lymphocyte ratio (NLR) and the effectiveness of immune checkpoint inhibitor (ICI) plus platinum doublet remains unknown, despite several reported prognostic models. We used real-world data to investigate whether baseline medications plus NLR predict survival outcomes in patients with advanced non-small-cell lung cancer (NSCLC) receiving ICI plus platinum doublet. This multicenter, retrospective, observational study conducted in Japan between December 2018 and March 2021 used real-world data of consecutive patients with advanced NSCLC who received ICI (pembrolizumab or atezolizumab) plus platinum doublet as first-line treatment.
View Article and Find Full Text PDFArticle Synopsis
- This study compared the effectiveness and safety of a filgrastim biosimilar (F-BS) to the original filgrastim in treating malignant lymphoma in 78 patients undergoing CHASE (± R) or DeVIC (± R) therapies.
- Results showed that both groups had similar median doses of treatment, days to neutrophil recovery, and incidences of febrile neutropenia (FN), indicating comparable efficacy and safety between F-BS and original filgrastim.
- Additionally, using F-BS resulted in lower medical costs, saving about $170.22 per course of CHASE (± R) therapy.
Purpose: This study aimed to identify patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) in patients with cancer receiving carboplatin in addition to standard antiemetics, using real-world data.
Methods: In this single-center, observational study, data from electronic medical records of consecutive patients with solid tumors who had received their first cycle of a carboplatin-based regimen and were treated with a 2- or 3-drug combination of antiemetics from January 2014 to January 2019 at Toranomon Hospital were retrospectively analyzed. The primary end point was the occurrence of a complete response (CR) within 5 days after the first cycle, which was defined as no vomiting and no use of rescue medication for CINV.